Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | $37.5K | — | — | — | — | — | — | — | — | — |
| Operating income | -$2.12M | -$2.40M | -$5.33M | -$11.0M | -$11.9M | -$23.4M | -$116M | -$38.6M | -$81.6M | -$189M |
| Net income | -$1.74M | -$2.14M | -$6.31M | -$18.0M | -$11.4M | -$26.7M | -$113M | -$39.7M | -$88.4M | -$178M |
| EPS (diluted) | -$0.18 | -$0.17 | -$0.29 | -$0.48 | -$0.25 | -$0.57 | -$2.16 | -$0.71 | -$0.91 | -$1.08 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.47M | -$1.18M | -$4.34M | -$8.51M | -$10.5M | -$20.6M | -$15.7M | -$11.8M | -$11.0M | -$7.87M |
| Capital expenditures | — | — | $30.0K | $717K | $184K | $48.9K | $5.16K | $29.8K | $70.4K | — |
| Free cash flow | — | — | -$4.37M | -$9.22M | -$10.6M | -$20.7M | -$15.7M | -$11.8M | -$11.0M | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $23.4K | $3.94M | $15.6M | $12.3M | $8.70M | $20.7M | $9.17M | $1.87M | $220K | $92.7K |
| Total assets | $871K | $4.52M | $183M | $180M | $178M | $190M | $84.6M | $58.3M | $163M | $8.23M |
| Total liabilities | $1.51M | $2.99M | $23.8M | $6.78M | $11.8M | $14.9M | $12.0M | $11.8M | $31.2M | $29.6M |
| Long-term debt | $103K | — | — | — | — | — | — | — | — | — |
| Shareholders' equity | -$637K | $1.53M | $159M | $173M | $166M | $175M | $72.6M | $46.5M | $132M | -$21.3M |
| Retained earnings | -$26.3M | -$28.4M | -$34.8M | -$52.8M | -$64.2M | -$90.9M | -$204M | -$244M | -$332M | -$510M |
| Shares (wtd avg diluted) | 9.53M | 12.3M | 36.2M | 45.3M | 46.5M | 52.2M | 52.5M | 56.3M | 97.5M | 165M |
Every figure is extracted from Lunai Bioworks Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.